Astellas Submits Fezolinetant New Drug Application to U.S. FDA

astellas submits fezolinetant new drug application to u s fda

Pressbee - PR Newswire :

Watch the post from Astellas Submits Fezolinetant New Drug Application to U.S. FDA, Now to the details :

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for fezolinetant...

For more, read the news from the source

Astellas Submits Fezolinetant New Drug Application to U.S. FDA

This was the summery for Astellas Submits Fezolinetant New Drug Application to U.S. FDA We hope that we have succeeded by sharing the full details of this topic.

PR Newswire Astellas Submits Fezolinetant New Drug Application to U.S. FDA Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for fezolinetant...

Please note that the original topic has been published and is available on PR Newswire the editing team at PressBee have verified it and it may have been partially modified or quoted from it. You can read and follow this news or topic from its main source.

( PRESSBEE ) An independent news reader does not assume any liability for the material published in it because it does not express the opinion of the site.